EP4302777A4 - ANTI-CLDN6 ANTIBODIES AND USE THEREOF - Google Patents

ANTI-CLDN6 ANTIBODIES AND USE THEREOF

Info

Publication number: EP4302777A4
Authority: EP; European Patent Office
Prior art keywords: cldn6 antibodies; cldn6; antibodies
Prior art date: 2021-03-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Other versions

Inventor

Liang Du

Hongyan Zhang

Lina Jin

Yali Chen

Tingting Wan

Liuliu Xu

Jijun Yuan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Shanghai Genbase Biotechnology Co Ltd

Original Assignee

Shanghai Genbase Biotechnology Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2021-03-05

Filing date

2021-03-05

Publication date

2025-07-02

2021-03-05Application filed by Shanghai Genbase Biotechnology Co LtdfiledCriticalShanghai Genbase Biotechnology Co Ltd

2024-01-10Publication of EP4302777A1publicationCriticalpatent/EP4302777A1/en

2025-07-02Publication of EP4302777A4publicationCriticalpatent/EP4302777A4/en

StatusPendinglegal-statusCriticalCurrent

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Hematology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Hospice & Palliative Care (AREA)
Mycology (AREA)
Endocrinology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Pathology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

EP21928585.5A2021-03-052021-03-05 ANTI-CLDN6 ANTIBODIES AND USE THEREOFPendingEP4302777A4 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/CN2021/079380WO2022183502A1 (en)	2021-03-05	2021-03-05	Anti-cldn6 antibody and use thereof

Publications (2)

Publication Number	Publication Date
EP4302777A1 EP4302777A1 (en)	2024-01-10
EP4302777A4true EP4302777A4 (en)	2025-07-02

Family

ID=83154900

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP21928585.5APendingEP4302777A4 (en)	2021-03-05	2021-03-05	ANTI-CLDN6 ANTIBODIES AND USE THEREOF

Country Status (8)

Country	Link
US (1)	US20240150455A1 (en)
EP (1)	EP4302777A4 (en)
JP (1)	JP7734753B2 (en)
KR (1)	KR20230154317A (en)
CN (1)	CN116940377A (en)
CA (1)	CA3212530A1 (en)
TW (1)	TW202235441A (en)
WO (1)	WO2022183502A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL313018A (en)*	2021-12-17	2024-07-01	Tnax Biopharma Corp	Humanized antibody against DNAM-1
WO2024165057A1 (en)	2023-02-07	2024-08-15	LaNova Medicines Limited	Antibodies and antibody-drug conjugates targeting claudin 6
CN118878678A (en)*	2023-04-30	2024-11-01	泰诚思(上海)生物医药有限公司	Antigen binding protein of hCLDN6 and its use
US20250121084A1 (en)*	2023-10-17	2025-04-17	Adc Therapeutics Sa	Anti-claudin-6 conjugates
WO2025083067A1 (en)*	2023-10-17	2025-04-24	Adc Therapeutics Sa	Anti-claudin-6 conjugates
CN118772280B (en)*	2024-06-13	2025-04-04	广州百吉生物制药有限公司	An anti-human CLDN6 single domain antibody and its application
CN118754987B (en)*	2024-08-21	2025-02-11	广州百吉生物制药有限公司	A tight junction protein antibody H04 and its application
CN118812714B (en)*	2024-08-21	2025-05-27	广州百吉生物制药有限公司	Tight junction protein antibody B3 and application thereof
CN120757650A (en)*	2024-11-08	2025-10-10	深圳豪石生物科技有限公司	CLDN6 single-domain antibodies and their humanization

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2241578A1 (en)*	2008-01-11	2010-10-20	The University of Tokyo	Anti-cldn6 antibody
WO2011057788A1 (en)*	2009-11-11	2011-05-19	Ganymed Pharmaceuticals Ag	Antibodies specific for claudin 6 (cldn6)
WO2015069794A2 (en)*	2013-11-06	2015-05-14	Stem Centrx, Inc.	Novel anti-claudin antibodies and methods of use
WO2016073649A1 (en)*	2014-11-05	2016-05-12	Stemcentrx, Inc.	Anti-cldn chimeric antigen receptors and methods of use
WO2020191344A1 (en)*	2019-03-20	2020-09-24	The Regents Of The University Of California	Claudin-6 bispecific antibodies
WO2020191342A1 (en)*	2019-03-20	2020-09-24	The Regents Of The University Of California	Claudin-6 antibodies and drug conjugates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154598B (en)	1970-11-10	1977-09-15	Organon Nv	PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3939350A (en)	1974-04-29	1976-02-17	Board Of Trustees Of The Leland Stanford Junior University	Fluorescent immunoassay employing total reflection for activation
US3996345A (en)	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4277437A (en)	1978-04-05	1981-07-07	Syva Company	Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en)	1980-08-07	1982-12-28	Syva Company	Concentrating zone method in heterogeneous immunoassays
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ES2405944T3 (en)	2000-11-30	2013-06-04	Medarex, Inc.	Nucleic acids encoding reorganized human immunoglobulin sequences from transgenic transchromosomal micezadas
AU2010301042B2 (en)	2009-10-01	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
CA2851795C (en)	2011-10-20	2018-11-13	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-cd22 chimeric antigen receptors
WO2013126726A1 (en)	2012-02-22	2013-08-29	The Trustees Of The University Of Pennsylvania	Double transgenic t cells comprising a car and a tcr and their methods of use

2021
- 2021-03-05EPEP21928585.5Apatent/EP4302777A4/enactivePending
- 2021-03-05KRKR1020237033643Apatent/KR20230154317A/enactivePending
- 2021-03-05CACA3212530Apatent/CA3212530A1/enactivePending
- 2021-03-05JPJP2023553642Apatent/JP7734753B2/enactiveActive
- 2021-03-05CNCN202180095157.5Apatent/CN116940377A/enactivePending
- 2021-03-05USUS18/280,379patent/US20240150455A1/enactivePending
- 2021-03-05WOPCT/CN2021/079380patent/WO2022183502A1/ennot_activeCeased
2022
- 2022-03-01TWTW111107215Apatent/TW202235441A/enunknown

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2241578A1 (en)*	2008-01-11	2010-10-20	The University of Tokyo	Anti-cldn6 antibody
WO2011057788A1 (en)*	2009-11-11	2011-05-19	Ganymed Pharmaceuticals Ag	Antibodies specific for claudin 6 (cldn6)
WO2015069794A2 (en)*	2013-11-06	2015-05-14	Stem Centrx, Inc.	Novel anti-claudin antibodies and methods of use
WO2016073649A1 (en)*	2014-11-05	2016-05-12	Stemcentrx, Inc.	Anti-cldn chimeric antigen receptors and methods of use
WO2020191344A1 (en)*	2019-03-20	2020-09-24	The Regents Of The University Of California	Claudin-6 bispecific antibodies
WO2020191342A1 (en)*	2019-03-20	2020-09-24	The Regents Of The University Of California	Claudin-6 antibodies and drug conjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references ofWO2022183502A1*

Also Published As

Publication number	Publication date
US20240150455A1 (en)	2024-05-09
JP7734753B2 (en)	2025-09-05
WO2022183502A1 (en)	2022-09-09
CA3212530A1 (en)	2022-09-09
JP2024512337A (en)	2024-03-19
TW202235441A (en)	2022-09-16
CN116940377A (en)	2023-10-24
KR20230154317A (en)	2023-11-07
EP4302777A1 (en)	2024-01-10

Publication	Publication Date	Title
EP4141030A4 (en)	2024-09-04	ANTI-CD73 ANTIBODIES AND USE THEREOF
EP4039708A4 (en)	2023-11-08	ANTI-CLL-1 ANTIBODIES AND USE THEREOF
EP4159763A4 (en)	2024-06-12	ANTI-CD73 ANTIBODIES AND USE THEREOF
EP3907240A4 (en)	2023-02-22	ANTI-TNFR2 ANTIBODIES AND USE THEREOF
EP3904386A4 (en)	2022-09-07	ANTIBODIES AND USE THEREOF
EP4302777A4 (en)	2025-07-02	ANTI-CLDN6 ANTIBODIES AND USE THEREOF
EP3999545A4 (en)	2023-09-13	ANTI-CD73 ANTIBODIES AND USE THEREOF
EP3802612A4 (en)	2022-03-23	ANTI-B7-H3 ANTIBODIES AND USE THEREOF
EP3962956A4 (en)	2023-06-07	ANTI-HVEM ANTIBODIES AND USE THEREOF
EP4249514A4 (en)	2024-10-16	BISPECIFIC ANTIBODIES AND USE THEREOF
EP4321535A4 (en)	2025-04-23	ANTI-CNTN4 ANTIBODIES AND USE THEREOF
EP4141033A4 (en)	2024-05-29	ANTI-CD73-ANTI-PD-1 BISPECIFIC ANTIBODY AND USE THEREOF
EP4201958A4 (en)	2024-09-04	ANTI-CTLA-4 ANTIBODIES AND USE THEREOF
EP4353249A4 (en)	2025-07-09	MULTIAGONIST AND USE THEREOF
EP4276112A4 (en)	2025-03-12	ANTI-FGFR3 ANTIBODIES AND USE THEREOF
EP4359442A4 (en)	2025-10-15	ANTI-CCR8 ANTIBODIES AND USES THEREOF
EP4132569A4 (en)	2024-07-31	ANTI-PHF-TAU ANTIBODIES AND USES THEREOF
EP4126938A4 (en)	2024-04-10	SIGLEC15-BINDING ANTIBODIES AND USES THEREOF
EP4375299A4 (en)	2025-07-16	B7-H3 ANTIBODIES AND USE THEREOF
EP4242232A4 (en)	2024-09-11	BISPECIFIC ANTIBODY AND USE THEREOF
EP4247419A4 (en)	2024-11-06	ANTI-MARCO ANTIBODIES AND USES THEREOF
EP4244255A4 (en)	2024-12-25	ANTI-TIGIT ANTIBODIES AND USES THEREOF
EP4146272A4 (en)	2024-10-23	COVID-19 ANTIBODIES AND USES THEREOF
EP4142793A4 (en)	2024-08-28	ABCB5-SPECIFIC ANTIBODIES AND USES THEREOF
EP4321536A4 (en)	2025-02-26	BISPECIFIC ANTIBODIES AND USE THEREOF

Legal Events

Date	Code	Title	Description
2022-09-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text:STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2023-12-08	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text:ORIGINAL CODE: 0009012
2023-12-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text:STATUS: REQUEST FOR EXAMINATION WAS MADE
2024-01-10	17P	Request for examination filed	Effective date:20230908
2024-01-10	AK	Designated contracting states	Kind code of ref document:A1 Designated state(s):AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2024-06-12	DAV	Request for validation of the european patent (deleted)
2024-06-12	DAX	Request for extension of the european patent (deleted)
2025-02-04	REG	Reference to a national code	Ref country code:DE Ref legal event code:R079 Free format text:PREVIOUS MAIN CLASS: A61K0039395000 Ipc:C07K0016280000
2025-03-12	RIC1	Information provided on ipc code assigned before grant	Ipc:C12N 15/13 20060101ALI20250204BHEP Ipc:A61P 35/00 20060101ALI20250204BHEP Ipc:A61K 39/395 20060101ALI20250204BHEP Ipc:C07K 16/30 20060101ALI20250204BHEP Ipc:C07K 16/28 20060101AFI20250204BHEP
2025-07-02	A4	Supplementary search report drawn up and despatched	Effective date:20250603
2025-07-02	RIC1	Information provided on ipc code assigned before grant	Ipc:C12N 15/13 20060101ALI20250527BHEP Ipc:A61P 35/00 20060101ALI20250527BHEP Ipc:A61K 39/395 20060101ALI20250527BHEP Ipc:C07K 16/30 20060101ALI20250527BHEP Ipc:C07K 16/28 20060101AFI20250527BHEP

Movatterモバイル変換